Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moleculin Biotech

0.3019
-0.0103-3.30%
Pre-market: 0.2959-0.0060-1.99%08:04 EDT
Volume:2.57M
Turnover:769.79K
Market Cap:7.28M
PE:-0.07
High:0.3122
Open:0.3122
Low:0.2900
Close:0.3122
Loading ...

Moleculin Biotech Faces Nasdaq Delisting Warning

TIPRANKS
·
28 Jun

Moleculin Biotech Inc - Receives Nasdaq Deficiency Letter for Bid Price - SEC Filing

THOMSON REUTERS
·
28 Jun

Moleculin Biotech Inc. Receives Nasdaq Deficiency Notice for Falling Below Minimum Bid Price Requirement

Reuters
·
28 Jun

Roth MKM Remains a Buy on Moleculin Biotech (MBRX)

TIPRANKS
·
27 Jun

Moleculin Biotech Raises $5.9M in Public Offering

TIPRANKS
·
24 Jun

Walter V. Klemp, CEO and President, Reports Acquisition of Common Shares of Moleculin Biotech Inc

Reuters
·
24 Jun

Moleculin Biotech prices 16.08M shares at 37c in public offering

TIPRANKS
·
20 Jun

Moleculin Announces $5.9 Million Public Offering

THOMSON REUTERS
·
20 Jun

Moleculin Biotech Inc - Prices Public Offering at $0.37 per Share

THOMSON REUTERS
·
20 Jun

Moleculin Biotech Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Jun

Promising Developments and Regulatory Progress Drive Buy Rating for Moleculin Biotech’s Annamycin

TIPRANKS
·
18 Jun

Moleculin Participates in Virtual Investor “What This Means” Segment

GlobeNewswire
·
18 Jun

Moleculin Biotech Inc. Receives Positive FDA Feedback for Pediatric Study Plan of Annamycin in Children with R/R AML

Reuters
·
18 Jun

Moleculin Biotech Inc - Expects to Initiate Pediatric Study in Second Half of 2027

THOMSON REUTERS
·
18 Jun

Moleculin Biotech Inc - FDA Allows Pediatric Trial to Start Before Full Adult Data

THOMSON REUTERS
·
18 Jun

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children With R/R Aml

THOMSON REUTERS
·
18 Jun

Moleculin Biotech announces ‘What This Means’ virtual investor segment

TIPRANKS
·
11 Jun

Moleculin Biotech Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $4

THOMSON REUTERS
·
09 Jun

Moleculin Biotech Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
09 Jun

Moleculin Biotech: Positive Clinical Trial Results and Strategic Developments Support Buy Rating

TIPRANKS
·
06 Jun